Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15451 - 15475 of 15602 in total
TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.
Investigational
MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer. AraC's anti-cancer activity is associated with its ability to be converted to its biologically active form, araCTP. However, araC is only slowly...
Investigational
Experimental
SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes.
Investigational
Experimental
Vet approved
Matched Iupac: … 'R,7aR)-6-{[(2S,3R,4R,5S,6R)-2-{[(2R,3S,4S,5S,6S)-6-[(2R,3aS,3'aR,6'R,7R,7'S,7aR,7'aR)-7'-acetyl-6'-methyl
Experimental
Experimental
Napabucasin has been investigated for the treatment of Colorectal Carcinoma.
Investigational
Pridopidine has been used in trials studying the treatment of Huntington's Disease.
Investigational
Experimental
Zanapezil (TAK-147) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment.
Investigational
Experimental
Experimental
This drug is a dissociative anesthetic agent that falls under the drug category of NMDA receptor antagonists. Tiletamine is chemically similar to another dissociative anesthetic, ketamine. Tiletamine hydrochloride, the salt form, exists as odorless white crystals.
Vet approved
Displaying drugs 15451 - 15475 of 15602 in total